Document 0234
 DOCN  M9440234
 TI    Improved cell-mediated immune responses in HIV-1-infected asymptomatic
       individuals after immunization with envelope glycoprotein gp160.
 DT    9404
 AU    Wahren B; Bratt G; Persson C; Leven B; Hinkula J; Gilljam G; Nordlund S;
       Eriksson L; Volvovitz F; Broliden PA; et al; Department of Virology,
       South Hospital, Stockholm, Sweden.
 SO    J Acquir Immune Defic Syndr. 1994 Mar;7(3):220-9. Unique Identifier :
       AIDSLINE MED/94149555
 AB    Strong specific T-cell responses to human immunodeficiency virus type 1
       (HIV-1) gp160 were induced by immunization with recombinant gp160
       (rgp160). It was given as postinfection vaccination to 40 asymptomatic
       HIV-1 seropositive patients. The participants received 6 doses of 160
       micrograms rgp160 administered intramuscularly at 0, 1, 4, 8, 17, and 26
       weeks and were monitored for 1 year. Lymphocyte proliferation was
       performed by cultivating lymphoid cells in vitro with specific antigens
       and mitogens. After immunization with gp160, specific T-cell
       proliferative responses were induced in all 40 patients. One week after
       the sixth immunization at day 180, a substantially increased response
       was detected in 98% of the patients, with a mean stimulation index value
       of 195. Furthermore, proliferative responses were also identified, after
       immunization, against native gp120 and against a peptide representing
       the V3 region of gp120. In addition to the HIV-specific T-cell
       responses, increased reactivity to several other non-HIV antigens,
       including tetanus toxoid, influenza, measles, and cytomegalovirus, were
       seen after gp160 vaccination. The responses to CMV and measles were
       interpreted to represent an improved recall antigen response. Such
       recall antigen responses were few in matched HIV-infected controls
       immunized with influenza virus only. All patients initially and
       repeatedly showed a normal capacity of total T-cell activation,
       evaluated by the mitogen phytohemagglutinin (PHA). The trend in CD4
       counts improved in 30 of 40 patients during the year of follow-up. The
       frequency of increases of proliferative responses to antigens was
       associated with a better CD4 trend. Addition of zidovudine for 2 weeks
       after each immunization had no beneficial effects nor did it prevent
       induction of immune responses. All patients tolerated the immunizations
       well, and no systemic adverse effects were noted. This is a phase I
       trial, and no definitive conclusions regarding clinical efficacy can be
       reached.
 DE    Adult  Female  Follow-Up Studies  Gene Products, env/*IMMUNOLOGY  Human
       HIV/*IMMUNOLOGY  HIV Core Protein p24/IMMUNOLOGY  HIV Envelope Protein
       gp120/IMMUNOLOGY  HIV Seropositivity/DRUG THERAPY/*IMMUNOLOGY  Immunity,
       Cellular  *Immunization  Immunization, Secondary  Leukocyte Count
       Lymphocyte Transformation  Male  Middle Age  Peptide
       Fragments/IMMUNOLOGY  Protein Precursors/*IMMUNOLOGY  Recombinant
       Proteins/IMMUNOLOGY  T4 Lymphocytes/*IMMUNOLOGY  Zidovudine/THERAPEUTIC
       USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).